Blood Cancer United's new research funding supports foundational science, AI, big data and global collaborations to improve patient outcomes WASHINGTON, Dec. 2, 2025 /PRNewswire/ ...

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...

Researchers sought to determine whether adding mogamulizumab to CHOP would improve outcomes in older patients with adult T-cell leukemia/lymphoma.

(hereinafter referred to as “Juventas”) announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug ...

Progress in the treatment of T-cell blood cancers – which are rare – has also been modest. So, much remains to be done to ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents ...

Bristol Myers Squibb (BMY), on Tuesday, announced that it has received approval from the European Commission to expand the use of its CAR T cell therapy Breyanzi for relapsed ...

And they received FDA support for Orphan Drug Designation and Fast Track Designation and they've got the opportunity to look at the IIb turning into a registration study, and that opens up the ...

In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients still ...

HACKENSACK, N.J., Nov. 21, 2025 /PRNewswire/ — Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated Lombardi Comprehensive Cancer ...